This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Insiders Bullish on Certain Holdings of XBI

Stocks in this article: MACK

A look at the weighted underlying holdings of the SPDR S&P Biotech ETF (XBI) shows an impressive 13.1% of holdings on a weighted basis have experienced insider buying within the past six months.

START SLIDESHOW:
10 ETFs With Stocks That Insiders Are Buying »

Merrimack Pharmaceuticals Inc. (MACK), which makes up 2.12% of the SPDR S&P Biotech ETF (XBI), has seen 7 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $21,666,015 worth of MACK, making it the #2 largest holding. The table below details the recent insider buying activity observed at MACK:

MACK — last trade: $8.10 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
11/29/2013 Michael E. Porter Director 75,000 $3.60 $270,185.00
11/29/2013 William M. McClements SVP of Corporate Operations 7,000 $3.61 $25,255.00
11/29/2013 Anthony J. Sinskey Director 3,800 $3.92 $14,877.00
12/03/2013 Michael E. Porter Director 75,000 $4.17 $312,907.50
12/02/2013 William M. McClements SVP of Corporate Operations 2,000 $4.06 $8,119.20
12/03/2013 Sarah E. Nash Director 47,500 $4.17 $198,306.00
12/04/2013 Robert J. Mulroy President and CEO 33,100 $4.42 $146,225.87
12/06/2013 James H. Quigley Director 39,000 $4.70 $183,257.10
12/10/2013 Michael E. Porter Director 18,000 $4.38 $78,840.00
12/12/2013 William M. McClements SVP of Corporate Operations 4,000 $4.26 $17,059.20
12/17/2013 Michael E. Porter Director 25,000 $4.75 $118,811.25
05/05/2014 Michael E. Porter Director 15,000 $6.41 $96,150.00
05/05/2014 Gary L. Crocker Director 10,000 $6.69 $66,900.00
05/05/2014 Robert J. Mulroy President and CEO 5,000 $6.31 $31,550.00
05/06/2014 Gary L. Crocker Director 17,500 $6.89 $120,575.00
05/05/2014 Michael E. Porter Director 5,000 $6.12 $30,600.00
05/07/2014 Gary L. Crocker Director 4,400 $6.77 $29,788.00
05/07/2014 Sarah E. Nash Director 15,000 $6.79 $101,850.00
05/08/2014 Michael E. Porter Director 10,000 $6.59 $65,900.00
05/13/2014 Anthony J. Sinskey Director 5,000 $6.74 $33,700.00
05/16/2014 Michael E. Porter Director 15,000 $6.49 $97,400.00
05/19/2014 Gary L. Crocker Director 9,400 $6.68 $62,802.00
05/19/2014 James H. Quigley Director 5,000 $6.58 $32,900.00
05/20/2014 Gary L. Crocker Director 4,000 $6.69 $26,760.00

And Repligen Corp. (RGEN), the #5 largest holding among components of the SPDR S&P Biotech ETF (XBI), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $18,712,800 worth of RGEN, which represents approximately 1.83% of the ETF's total assets at last check. The recent insider buying activity observed at RGEN is detailed in the table below:

RGEN — last trade: $19.37 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
04/15/2014 James R. Rusche Senior Vice President 25,000 $3.05 $76,250.00
04/15/2014 Daniel P. Witt Senior Vice President 10,000 $3.05 $30,500.00

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs